New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer. AstraZeneca has been ...

On Wednesday, China approved AstraZeneca plc's (NYSE:AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with ...

Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted ...

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...

In the first quarter of 2024, Tagrisso recorded sales worth $1.60 billion, increasing 15% year over year at constant exchange rates, on strong demand as a first-line and adjuvant treatment.

In 2023, TAGRISSO® plus ORPATHYS® received Fast Track designation from the US Food and Drug Administration (FDA) in this setting. ORPATHYS® is an oral, potent, and highly selective MET tyrosine ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of ...